Targeted Peptide Measurements in Biology and Medicine: Best Practices for Mass Spectrometry-based Assay Development Using a Fit-for-Purpose Approach*

Adoption of targeted mass spectrometry (MS) approaches such as multiple reaction monitoring (MRM) to study biological and biomedical questions is well underway in the proteomics community. Successful application depends on the ability to generate reliable assays that uniquely and confidently identify target peptides in a sample. Unfortunately, there is a wide range of criteria being applied to say that an assay has been successfully developed. There is no consensus on what criteria are acceptable and little understanding of the impact of variable criteria on the quality of the results generated. Publications describing targeted MS assays for peptides frequently do not contain sufficient information for readers to establish confidence that the tests work as intended or to be able to apply the tests described in their own labs. Guidance must be developed so that targeted MS assays with established performance can be made widely distributed and applied by many labs worldwide. To begin to address the problems and their solutions, a workshop was held at the National Institutes of Health with representatives from the multiple communities developing and employing targeted MS assays. Participants discussed the analytical goals of their experiments and the experimental evidence needed to establish that the assays they develop work as intended and are achieving the required levels of performance. Using this “fit-for-purpose” approach, the group defined three tiers of assays distinguished by their performance and extent of analytical characterization. Computational and statistical tools useful for the analysis of targeted MS results were described. Participants also detailed the information that authors need to provide in their manuscripts to enable reviewers and readers to clearly understand what procedures were performed and to evaluate the reliability of the peptide or protein quantification measurements reported. This paper presents a summary of the meeting and recommendations.

[1]  Whole Grain Label Statements.  Guidance for Industry and FDA Staff , 2006 .

[2]  Pei Wang,et al.  The interface between biomarker discovery and clinical validation: The tar pit of the protein biomarker pipeline , 2008, Proteomics. Clinical applications.

[3]  Ruedi Aebersold,et al.  Automated selected reaction monitoring data analysis workflow for large-scale targeted proteomic studies , 2013, Nature Protocols.

[4]  Hendrik Neubert,et al.  Sequential protein and peptide immunoaffinity capture for mass spectrometry-based quantification of total human β-nerve growth factor. , 2013, Analytical chemistry.

[5]  S. Grebe,et al.  LC-MS/MS in the Clinical Laboratory - Where to From Here? , 2011, The Clinical biochemist. Reviews.

[6]  B. Favrat,et al.  Validation of hepcidin quantification in plasma using LC-HRMS and discovery of a new hepcidin isoform. , 2013, Bioanalysis.

[7]  T. Larson,et al.  A liquid chromatography-mass spectrometry method for the quantification of urinary albumin using a novel 15N-isotopically labeled albumin internal standard. , 2007, Clinical chemistry.

[8]  L. A. Currie,et al.  LIMITS FOR QUALITATIVE DETECTION AND QUANTITATIVE DETERMINATION. APPLICATION TO RADIOCHEMISTRY. , 1968 .

[9]  David Fenyö,et al.  Mass spectrometric protein identification using the global proteome machine. , 2010, Methods in molecular biology.

[10]  Christoph H Borchers,et al.  Multiple Reaction Monitoring-based, Multiplexed, Absolute Quantitation of 45 Proteins in Human Plasma* , 2009, Molecular & Cellular Proteomics.

[11]  P. Massion,et al.  Methods for Peptide and Protein Quantitation by Liquid Chromatography-Multiple Reaction Monitoring Mass Spectrometry* , 2011, Molecular & Cellular Proteomics.

[12]  J. Vargo.  Determination of sulfonic acid degradates of chloroacetanilide and chloroacetamide herbicides in groundwater by LC/MS/MS. , 1998, Analytical chemistry.

[13]  Xu Shi,et al.  Quantification of Cardiovascular Biomarkers in Patient Plasma by Targeted Mass Spectrometry and Stable Isotope Dilution* , 2009, Molecular & Cellular Proteomics.

[14]  Martin Eisenacher,et al.  Guidelines for reporting quantitative mass spectrometry based experiments in proteomics. , 2013, Journal of proteomics.

[15]  B. Matuszewski,et al.  Matrix effect in quantitative LC/MS/MS analyses of biological fluids: a method for determination of finasteride in human plasma at picogram per milliliter concentrations. , 1998, Analytical chemistry.

[16]  J A Sphon,et al.  Use of mass spectrometry for confirmation of animal drug residues. , 1978, Journal - Association of Official Analytical Chemists.

[17]  L L Needham,et al.  Isotope dilution--mass spectrometric quantification of specific proteins: model application with apolipoprotein A-I. , 1996, Clinical chemistry.

[18]  K. Barnhart,et al.  Rapid verification of candidate serological biomarkers using gel-based, label-free multiple reaction monitoring. , 2011, Journal of proteome research.

[19]  O. Nemirovskiy,et al.  Clinical validation of an immunoaffinity LC-MS/MS assay for the quantification of a collagen type II neoepitope peptide: A biomarker of matrix metalloproteinase activity and osteoarthritis in human urine. , 2007, Analytical biochemistry.

[20]  Susan E Abbatiello,et al.  Automated detection of inaccurate and imprecise transitions in peptide quantification by multiple reaction monitoring mass spectrometry. , 2010, Clinical chemistry.

[21]  Lloyd A. Currie,et al.  Limits for qualitative detection and quantitative determination , 1968 .

[22]  Timothy Olah,et al.  Mechanistic investigation of ionization suppression in electrospray ionization , 2000, Journal of the American Society for Mass Spectrometry.

[23]  Steven A. Carr,et al.  Updating the MCP Proteomic Publication Guidelines , 2009 .

[24]  J. Garin,et al.  Isotope dilution strategies for absolute quantitative proteomics. , 2009, Journal of proteomics.

[25]  Johannes Griss,et al.  The Proteomics Identifications (PRIDE) database and associated tools: status in 2013 , 2012, Nucleic Acids Res..

[26]  H. Parsons.  Stable isotopes in the management and diagnosis of inborn errors of metabolism. , 1990, Canadian journal of physiology and pharmacology.

[27]  Ruedi Aebersold,et al.  The Mtb proteome library: a resource of assays to quantify the complete proteome of Mycobacterium tuberculosis. , 2013, Cell host & microbe.

[28]  S. Stein,et al.  Establishing the fitness for purpose of mass spectrometric methods , 2003, Journal of the American Society for Mass Spectrometry.

[29]  Sam H Haidar,et al.  2012 white paper on recent issues in bioanalysis and alignment of multiple guidelines. , 2012, Bioanalysis.

[30]  John Chilton,et al.  Using iRT, a normalized retention time for more targeted measurement of peptides , 2012, Proteomics.

[31]  L. Cohen,et al.  Quantitation of endogenous analytes in biofluid without a true blank matrix. , 2003, Analytical chemistry.

[32]  A. Lawson.  The scope of mass spectrometry in clinical chemistry. , 1975, Clinical chemistry.

[33]  Fabio Garofolo,et al.  Bioanalytical Method Validation , 2004 .

[34]  Brendan MacLean,et al.  Bioinformatics Applications Note Gene Expression Skyline: an Open Source Document Editor for Creating and Analyzing Targeted Proteomics Experiments , 2022 .

[35]  Jeffrey R. Whiteaker,et al.  Sequential Multiplexed Analyte Quantification Using Peptide Immunoaffinity Enrichment Coupled to Mass Spectrometry* , 2011, Molecular & Cellular Proteomics.

[36]  Robert L. Moritz,et al.  An assessment of current bioinformatic solutions for analyzing LC‐MS data acquired by selected reaction monitoring technology , 2012, Proteomics.

[37]  Viswanath Devanarayan,et al.  Fit-for-Purpose Method Development and Validation for Successful Biomarker Measurement , 2006, Pharmaceutical Research.

[38]  Jonathan F. Russell,et al.  If a job is worth doing, it is worth doing twice , 2013, Nature.

[39]  Deepak R. Mani,et al.  Statistical characterization of multiple-reaction monitoring mass spectrometry (MRM-MS) assays for quantitative proteomics , 2012, BMC Bioinformatics.

[40]  Ruedi Aebersold,et al.  The Need for Guidelines in Publication of Peptide and Protein Identification Data , 2004, Molecular & Cellular Proteomics.

[41]  D. Dominguez,et al.  Proteomics: Clinical Applications , 2007, American Society for Clinical Laboratory Science.

[42]  R. Sederoff,et al.  Peptide Production and Decay Rates Affect the Quantitative Accuracy of Protein Cleavage Isotope Dilution Mass Spectrometry (PC-IDMS)* , 2012, Molecular & Cellular Proteomics.

[43]  Samuel I. Miller,et al.  Precursor acquisition independent from ion count: how to dive deeper into the proteomics ocean. , 2009, Analytical chemistry.

[44]  Philip Timmerman,et al.  'Large Meets Small': connecting the bioanalytical community around peptide and protein bioanalysis with LC-MS(/MS). , 2012, Bioanalysis.

[45]  D R Mani,et al.  Interlaboratory Evaluation of Automated, Multiplexed Peptide Immunoaffinity Enrichment Coupled to Multiple Reaction Monitoring Mass Spectrometry for Quantifying Proteins in Plasma* , 2011, Molecular & Cellular Proteomics.

[46]  Levon M Khachigian,et al.  DNAzyme Targeting c-jun Suppresses Skin Cancer Growth , 2012, Science Translational Medicine.

[47]  Richard Z. Liu,et al.  A database of reaction monitoring mass spectrometry assays for elucidating therapeutic response in cancer , 2011, Proteomics. Clinical applications.

[48]  J Cummings,et al.  Fit-for-purpose biomarker method validation for application in clinical trials of anticancer drugs , 2010, British Journal of Cancer.

[49]  Lukas N. Mueller,et al.  Full Dynamic Range Proteome Analysis of S. cerevisiae by Targeted Proteomics , 2009, Cell.

[50]  Jurgen Burhenne,et al.  Bioanalytical method validation , 2008 .

[51]  S. Carr,et al.  Quantitative analysis of peptides and proteins in biomedicine by targeted mass spectrometry , 2013, Nature Methods.

[52]  S. Carr,et al.  Quantitative, Multiplexed Assays for Low Abundance Proteins in Plasma by Targeted Mass Spectrometry and Stable Isotope Dilution*S , 2007, Molecular & Cellular Proteomics.

[53]  Eric W. Deutsch,et al.  The PeptideAtlas project , 2005, Nucleic Acids Res..

[54]  P. Timmerman,et al.  Best practices in a tiered approach to metabolite quantification: views and recommendations of the European Bioanalysis Forum. , 2010, Bioanalysis.

[55]  Jacob D. Jaffe,et al.  Global chromatin profiling reveals NSD2 mutations in pediatric acute lymphoblastic leukemia , 2013, Nature Genetics.

[56]  Michael H. Ramsey,et al.  Quality concepts and practices applied to sampling—an exploratory study , 1995 .

[57]  T. Kuhara.  Noninvasive human metabolome analysis for differential diagnosis of inborn errors of metabolism. , 2007, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[58]  Steven A Carr,et al.  Protein biomarker discovery and validation: the long and uncertain path to clinical utility , 2006, Nature Biotechnology.

[59]  Henry H. N. Lam,et al.  A database of mass spectrometric assays for the yeast proteome , 2008, Nature Methods.

[60]  F. Vandenesch,et al.  Isotope-labeled Protein Standards , 2007, Molecular & Cellular Proteomics.

[61]  A. Hoofnagle,et al.  Measurement of thyroglobulin by liquid chromatography-tandem mass spectrometry in serum and plasma in the presence of antithyroglobulin autoantibodies. , 2013, Clinical chemistry.

[62]  Kristian Linnet,et al.  Partly nonparametric approach for determining the limit of detection. , 2004, Clinical chemistry.

[63]  Christoph H Borchers,et al.  Multi-site assessment of the precision and reproducibility of multiple reaction monitoring–based measurements of proteins in plasma , 2009, Nature Biotechnology.

[64]  R. Aebersold,et al.  mProphet: automated data processing and statistical validation for large-scale SRM experiments , 2011, Nature Methods.

[65]  Olga Vitek,et al.  Statistical design of quantitative mass spectrometry-based proteomic experiments. , 2009, Journal of proteome research.

[66]  Ruedi Aebersold,et al.  High-throughput generation of selected reaction-monitoring assays for proteins and proteomes , 2010, Nature Methods.

[67]  Jingchun Chen,et al.  ATAQS: A computational software tool for high throughput transition optimization and validation for selected reaction monitoring mass spectrometry , 2011, BMC Bioinformatics.

[68]  Juncong Yang,et al.  MRM‐based multiplexed quantitation of 67 putative cardiovascular disease biomarkers in human plasma , 2012, Proteomics.

[69]  Bernhard Kuster,et al.  Quantitative mass spectrometry in proteomics: critical review update from 2007 to the present , 2012, Analytical and Bioanalytical Chemistry.

[70]  Daniel Figeys,et al.  Biomarker assay translation from discovery to clinical studies in cancer drug development: quantification of emerging protein biomarkers. , 2007, Advances in cancer research.

[71]  Ronald J. Moore,et al.  Antibody-free, targeted mass-spectrometric approach for quantification of proteins at low picogram per milliliter levels in human plasma/serum , 2012, Proceedings of the National Academy of Sciences.

[72]  P. Solter,et al.  Quantification of NTproBNP in rat serum using immunoprecipitation and LC/MS/MS: a biomarker of drug-induced cardiac hypertrophy. , 2008, Analytical chemistry.

[73]  J. Pitt,et al.  Comprehensive screening of urine samples for inborn errors of metabolism by electrospray tandem mass spectrometry. , 2002, Clinical chemistry.

[74]  Ludovic C. Gillet,et al.  Targeted Data Extraction of the MS/MS Spectra Generated by Data-independent Acquisition: A New Concept for Consistent and Accurate Proteome Analysis* , 2012, Molecular & Cellular Proteomics.

[75]  Luis Mendoza,et al.  PASSEL: The PeptideAtlas SRMexperiment library , 2012, Proteomics.

[76]  Pei Wang,et al.  A targeted proteomics–based pipeline for verification of biomarkers in plasma , 2011, Nature Biotechnology.

[77]  John D. Venable,et al.  Automated approach for quantitative analysis of complex peptide mixtures from tandem mass spectra , 2004, Nature Methods.

[78]  S. Carr,et al.  A pipeline that integrates the discovery and verification of plasma protein biomarkers reveals candidate markers for cardiovascular disease , 2011, Nature Biotechnology.

[79]  W. C. Brumley,et al.  Regulatory mass spectrometry. , 1981, Biomedical mass spectrometry.

[80]  Susan E Abbatiello,et al.  Evaluation of Large Scale Quantitative Proteomic Assay Development Using Peptide Affinity-based Mass Spectrometry* , 2011, Molecular & Cellular Proteomics.

[81]  S. Bates,et al.  European Bioanalysis Forum recommendation on method establishment and bioanalysis of biomarkers in support of drug development. , 2012, Bioanalysis.

[82]  Christophe Bruley,et al.  PSAQ™ standards for accurate MS-based quantification of proteins: from the concept to biomedical applications. , 2012, Journal of mass spectrometry : JMS.

[83]  Ralph A Bradshaw.  Revised draft guidelines for proteomic data publication. , 2005, Molecular & cellular proteomics : MCP.

[84]  R. Beynon,et al.  Multiplexed absolute quantification in proteomics using artificial QCAT proteins of concatenated signature peptides , 2005, Nature Methods.

[85]  Brendan MacLean,et al.  Label-Free Quantitation of Protein Modifications by Pseudo Selected Reaction Monitoring with Internal Reference Peptides , 2012, Journal of proteome research.

[86]  Eric W. Deutsch,et al.  PASSEL: The PeptideAtlas SRMexperiment library , 2012, Proteomics.

[87]  K. Kito,et al.  Mass Spectrometry-Based Approaches Toward Absolute Quantitative Proteomics , 2008, Current genomics.

[88]  Derek J. Bailey,et al.  Parallel Reaction Monitoring for High Resolution and High Mass Accuracy Quantitative, Targeted Proteomics* , 2012, Molecular & Cellular Proteomics.

[89]  Christoph H Borchers,et al.  Design, Implementation and Multisite Evaluation of a System Suitability Protocol for the Quantitative Assessment of Instrument Performance in Liquid Chromatography-Multiple Reaction Monitoring-MS (LC-MRM-MS)* , 2013, Molecular & Cellular Proteomics.

[90]  Hendrik Neubert,et al.  Online high-flow peptide immunoaffinity enrichment and nanoflow LC-MS/MS: assay development for total salivary pepsin/pepsinogen. , 2010, Clinical chemistry.

[91]  Jarrett D. Egertson,et al.  Multiplexed MS/MS for Improved Data Independent Acquisition , 2013, Nature Methods.

[92]  B. Domon,et al.  Targeted Proteomic Quantification on Quadrupole-Orbitrap Mass Spectrometer* , 2012, Molecular & Cellular Proteomics.

[93]  R. Aebersold,et al.  Selected reaction monitoring–based proteomics: workflows, potential, pitfalls and future directions , 2012, Nature Methods.

[94]  David R Goodlett,et al.  Multiplex targeted proteomic assay for biomarker detection in plasma: a pancreatic cancer biomarker case study. , 2012, Journal of proteome research.

[95]  S. Gygi,et al.  Absolute quantification of proteins and phosphoproteins from cell lysates by tandem MS , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[96]  Lisa M. Chung,et al.  Review of software tools for design and analysis of large scale MRM proteomic datasets. , 2013, Methods.

[97]  Eric W. Deutsch,et al.  A complete mass-spectrometric map of the yeast proteome applied to quantitative trait analysis , 2013, Nature.

[98]  R. Boyd,et al.  Mass spectrometry in trace analysis , 1998 .

[99]  K. Linnet,et al.  Evaluation of regression procedures for methods comparison studies. , 1993, Clinical chemistry.

[100]  Nichole L. King,et al.  The PeptideAtlas Project , 2010, Proteome Bioinformatics.

[101]  Ruedi Aebersold,et al.  Reproducible Quantification of Cancer-Associated Proteins in Body Fluids Using Targeted Proteomics , 2012, Science Translational Medicine.

[102]  C. Tian,et al.  Software for quantitative proteomic analysis using stable isotope labeling and data independent acquisition. , 2011, Analytical chemistry.